+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Metabolic Disorders Therapeutics Market - Global Forecast 2026-2032- Product Image
Metabolic Disorders Therapeutics Market - Global Forecast 2026-2032- Product Image
Sale

Metabolic Disorders Therapeutics Market - Global Forecast 2026-2032

  • Report

  • 195 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968659
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Metabolic Disorders Therapeutics Market is projected to reach USD 61.56 Billion in 2026. It is expected to continue growing at a CAGR of 6.31%, reaching USD 89.68 Billion by 2032.

Metabolic disorders therapeutics are moving from chronic symptom control toward disease-modifying, weight-centric, and cardiometabolic risk reduction strategies. The sector is anchored by diabetes, obesity, dyslipidemia, metabolic dysfunction-associated steatohepatitis, rare inborn errors of metabolism, and related renal and cardiovascular complications.

Demand is supported by verified epidemiology: the World Health Organization reports that more than 1 billion people were living with obesity in 2022, while diabetes affected about 830 million people worldwide in the same year. These burdens are expanding the clinical and commercial relevance of GLP-1 receptor agonists, dual and triple incretin therapies, SGLT2 inhibitors, lipid-lowering agents, RNA-based therapies, enzyme replacement approaches, and precision medicines for inherited metabolic diseases.

Transformative Shifts in the Therapeutic Landscape

The therapeutic landscape is being reshaped by the convergence of obesity medicine, diabetes care, liver disease management, kidney protection, and cardiovascular prevention. GLP-1 and GIP-based therapies have changed treatment expectations by demonstrating clinically meaningful weight loss and cardiometabolic benefits, while SGLT2 inhibitors have expanded beyond glucose lowering into heart failure and chronic kidney disease indications.

Regulatory science is also evolving. The approval of the first therapy for metabolic dysfunction-associated steatohepatitis with fibrosis in the United States signaled a new pathway for liver-metabolic drugs. At the same time, supply capacity, cold-chain reliability, payer affordability, device convenience, and long-term adherence are becoming decisive differentiators across metabolic disorders therapeutics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is accelerating metabolic disorders therapeutics through target discovery, biomarker identification, trial enrichment, pharmacovigilance, and real-world evidence generation. Machine learning models can integrate genomics, imaging, electronic health records, continuous glucose monitoring, laboratory values, and claims data to identify high-risk phenotypes and predict treatment response.

The impact is cumulative rather than isolated. AI-enabled patient stratification can improve clinical trial efficiency, while digital adherence tools, remote monitoring, and predictive analytics can support long-term outcomes in diabetes, obesity, dyslipidemia, and fatty liver disease. However, leaders must validate algorithms across diverse populations, protect patient data, reduce bias, and satisfy evolving regulatory expectations for clinical-grade AI.

Key Regional Insights Across Global Markets

Asia-Pacific is a high-volume region for metabolic disorders therapeutics, supported by large diabetes populations in China, India, Japan, South Korea, and Australia, rising obesity prevalence, and expanding access to specialty care. The International Diabetes Federation has consistently identified China and India among the countries with the largest adult diabetes populations, reinforcing the region’s importance for diabetes therapeutics, obesity drugs, lipid-lowering therapies, and renal-metabolic care. Japan, Australia, and South Korea add advanced clinical infrastructure, aging populations, and strong uptake potential for therapies with proven cardiovascular and renal outcomes.

North America remains a leading innovation and commercialization hub, supported by FDA regulatory pathways, high biologics adoption, robust clinical trial activity, and strong demand for obesity and cardiometabolic therapies. Latin America shows increasing need in Brazil and Mexico as diabetes and obesity rise, but reimbursement fragmentation and out-of-pocket exposure influence treatment continuity. Europe benefits from EMA oversight, health technology assessment discipline, and mature chronic disease programs, making comparative effectiveness and cost-effectiveness evidence central to access. The Middle East, especially Gulf markets, faces high diabetes prevalence and rapid specialty adoption, while Africa represents an underdiagnosed and access-constrained opportunity where affordable medicines, diagnostic scale-up, and primary care integration remain essential.

Key Group Insights for Strategic Prioritization

ASEAN demand is increasing as urbanization, dietary transition, and expanding health coverage raise diagnosis and treatment rates for type 2 diabetes, obesity, and dyslipidemia. GCC countries are prioritizing diabetes, obesity, and cardiovascular risk reduction through national health strategies, reflecting the region’s high metabolic disease burden and the growing relevance of premium metabolic therapies where reimbursement and specialist access allow.

The European Union is shaped by centralized regulatory review, national health technology assessment decisions, prescribing guidance, and cost-effectiveness scrutiny, making outcomes evidence critical for metabolic disorders therapeutics. BRICS countries combine large patient pools with varied pricing controls, access disparities, and local manufacturing priorities, particularly in diabetes medicines and cardiometabolic drugs. G7 markets lead in advanced incretin, lipid, renal-metabolic, and rare metabolic disease therapy adoption due to mature reimbursement systems and strong clinical infrastructure, while NATO countries increasingly frame medicine supply resilience, domestic capacity, and logistics security as part of broader health security planning.

Key Country Insights in Metabolic Disorders Therapeutics

The United States is an innovation-led market for metabolic disorders therapeutics, supported by high obesity prevalence, a substantial CDC-reported diabetes burden, rapid adoption of GLP-1 therapies, and strong clinical evidence requirements for cardiovascular, renal, and hepatic outcomes. Canada emphasizes a public-private reimbursement balance and evidence-based formulary decisions, while Mexico and Brazil offer large patient populations with persistent access, affordability, and care-continuity constraints that shape uptake of diabetes, obesity, and lipid-lowering therapies.

The United Kingdom, Germany, France, Italy, and Spain are guided by health technology assessment, prescribing protocols, budget impact reviews, and chronic disease pathways, making real-world outcomes and cost-offset evidence essential. Russia remains access-sensitive amid geopolitical and supply constraints. China and India combine massive diabetes and obesity-related disease burdens with price competition, expanding local manufacturing, and growing demand for scalable oral and injectable therapies. Japan, Australia, and South Korea offer advanced clinical infrastructure, aging populations, high standards for safety, and strong demand for long-term cardiometabolic treatments that reduce complications across diabetes, obesity, dyslipidemia, kidney disease, and cardiovascular risk.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical outcomes beyond weight loss or glucose reduction, including cardiovascular, renal, hepatic, lipid, functional, and quality-of-life endpoints. Portfolio strategy should balance premium biologics with scalable oral therapies, combination regimens, rare metabolic disease treatments, and lifecycle management that improves persistence and tolerability.

Organizations should build manufacturing redundancy, device-fill capacity, active pharmaceutical ingredient security, and cold-chain resilience to avoid supply bottlenecks in high-demand therapeutic classes. Market access teams should generate real-world evidence that supports cost offsets in diabetes complications, cardiovascular events, liver fibrosis progression, kidney disease outcomes, and hospitalization risk. Partnerships with diagnostics, digital health, primary care networks, and specialist clinics can strengthen patient identification, adherence, monitoring, and equitable access.

Research Methodology

This executive summary is based on secondary research from recognized public health, regulatory, clinical, and industry sources, including WHO, CDC, IDF, FDA, EMA, OECD, peer-reviewed journals, clinical guidelines, clinical trial registries, and public regulatory documents. The analysis prioritizes verified epidemiology, approved therapeutic classes, guideline-relevant treatment trends, regulatory milestones, and observable market access dynamics.

Insights were triangulated across disease burden, product innovation, reimbursement, regional access, healthcare infrastructure, and therapeutic adoption patterns. No unverified market-size, market-share, or forecast claims are used. Strategic conclusions reflect evidence-based interpretation of published data, regulatory actions, disease management priorities, and current clinical practice trends in metabolic disorders therapeutics.

Conclusion: Strategic Outlook for Metabolic Therapeutics

The metabolic disorders therapeutics market is entering a high-impact phase in which obesity, diabetes, liver disease, kidney disease, dyslipidemia, and cardiovascular prevention are increasingly treated as connected conditions. This shift supports strong demand for therapies that deliver durable, measurable, and multi-organ benefits while improving long-term disease management.

Future leadership will depend on evidence quality, differentiated outcomes, scalable manufacturing, equitable access, payer-ready real-world data, and responsible use of AI. Organizations that combine scientific innovation with region-specific commercialization models, resilient supply chains, and strong adherence support will be best positioned to capture long-term strategic value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Metabolic Disorders Therapeutics Market, by Treatment Classifications
7.1. Introduction
7.2. Enzyme Replacement Therapies
7.3. Gene Therapies
7.4. Medications & Drugs
7.5. Small Molecule Therapy
8. Metabolic Disorders Therapeutics Market, by Disease Type
8.1. Introduction
8.2. Diabetes Mellitus
8.2.1. Gestational Diabetes
8.2.2. Type 1 Diabetes
8.2.3. Type 2 Diabetes
8.3. Gaucher’s Disease
8.4. Hemochromatosis
8.5. Hypercholesterolemia
8.6. Mitochondrial Disorders
8.7. Phenylketonuria (PKU)
8.8. Pompe Disease
8.9. Thyroid Disorders
8.9.1. Hyperthyroidism
8.9.2. Hypothyroidism
8.10. Urea Cycle Disorders
8.11. Wilson's Disease
9. Metabolic Disorders Therapeutics Market, by Therapeutic Areas
9.1. Introduction
9.2. Endocrine Disorders
9.3. Genetic Disorders
9.4. Nutritional Disorders
10. Metabolic Disorders Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Metabolic Disorders Therapeutics Market, by Patient Demographics
11.1. Introduction
11.2. Adult Patients
11.3. Geriatric Patients
11.4. Pediatric Patients
12. Metabolic Disorders Therapeutics Market, by End User
12.1. Introduction
12.2. Clinics
12.3. Homecare Settings
12.4. Hospitals
12.5. Specialty Centers
13. Metabolic Disorders Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Metabolic Disorders Therapeutics Market, by Region
14.1. Asia-Pacific
14.2. North America
14.3. Latin America
14.4. Europe
14.5. Middle East
14.6. Africa
15. Metabolic Disorders Therapeutics Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Metabolic Disorders Therapeutics Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. FPNV Positioning Matrix, 2025
17.3. Market Concentration Analysis, 2025
17.3.1. Concentration Ratio (CR)
17.3.2. Herfindahl Hirschman Index (HHI)
17.4. Recent Developments & Impact Analysis, 2025
17.5. Product Portfolio Analysis, 2025
17.6. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Abbott Laboratories
18.2. AbbVie Inc.
18.3. Acadia Pharmaceuticals Inc.
18.4. Amgen Inc.
18.5. Amicus Therapeutics, Inc.
18.6. Astellas Pharma Inc.
18.7. AstraZeneca plc
18.8. Bayer AG
18.9. Biocon Limited
18.10. BioMarin Pharmaceutical Inc.
18.11. Boehringer Ingelheim International GmbH
18.12. CHIESI Farmaceutici S.p.A.
18.13. Dr. Reddy’s Laboratories Ltd.
18.14. Eli Lilly and Company
18.15. F. Hoffmann-La Roche Ltd
18.16. GlaxoSmithKline PLC
18.17. Glenmark Pharmaceuticals Limited
18.18. Johnson & Johnson Services, Inc.
18.19. Lupin Limited
18.20. Luye Pharma Group Ltd
18.21. Merck & Co., Inc.
18.22. Novartis AG
18.23. Novo Nordisk A/S
18.24. Otsuka Holdings Co., Ltd.
18.25. Pfizer Inc.
18.26. Recordati Industria Chimica e Farmaceutica S.p.A
18.27. Sanofi S.A.
18.28. Sumitomo Pharma Co., Ltd.
18.29. Sun Pharmaceutical Industries
18.30. Takeda Pharmaceutical Company Limited
18.31. Teva Pharmaceutical Industries Ltd.
18.32. Torrent Pharmaceuticals Ltd.
List of Figures
FIGURE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025 VS 2032 (%)
FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2032 (%)
FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 23. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 27. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ENZYME REPLACEMENT THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ENZYME REPLACEMENT THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ENZYME REPLACEMENT THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL GENE THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL GENE THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL GENE THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL MEDICATIONS & DRUGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL MEDICATIONS & DRUGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL MEDICATIONS & DRUGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL SMALL MOLECULE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SMALL MOLECULE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SMALL MOLECULE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DIABETES MELLITUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL DIABETES MELLITUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL DIABETES MELLITUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GESTATIONAL DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GESTATIONAL DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL GESTATIONAL DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL GAUCHER’S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL GAUCHER’S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL GAUCHER’S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL HEMOCHROMATOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL HEMOCHROMATOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL HEMOCHROMATOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL HYPERCHOLESTEROLEMIA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL MITOCHONDRIAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL PHENYLKETONURIA (PKU) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL PHENYLKETONURIA (PKU) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL PHENYLKETONURIA (PKU) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL THYROID DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL THYROID DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL THYROID DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HYPERTHYROIDISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HYPERTHYROIDISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HYPERTHYROIDISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL HYPOTHYROIDISM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL HYPOTHYROIDISM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL HYPOTHYROIDISM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL UREA CYCLE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL UREA CYCLE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL UREA CYCLE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL WILSON'S DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL WILSON'S DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL WILSON'S DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ENDOCRINE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL GENETIC DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL GENETIC DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL GENETIC DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL NUTRITIONAL DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL NUTRITIONAL DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NUTRITIONAL DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL HOMECARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL SPECIALTY CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 126. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 128. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 129. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 130. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 131. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 136. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 137. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 138. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 139. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 140. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 141. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 142. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 143. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 146. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 148. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 149. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 150. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 151. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 152. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 153. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 154. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. EUROPE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 158. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 159. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 160. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 161. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 162. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 164. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 165. MIDDLE EAST METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 166. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 167. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 168. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 169. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 170. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 171. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 172. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 173. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 174. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 178. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 179. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 180. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 181. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 182. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 183. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 184. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 185. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 186. ASEAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 187. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 188. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 189. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 190. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 191. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 192. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 193. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 194. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 195. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 196. GCC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 198. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 199. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 207. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 208. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 209. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 210. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 211. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 212. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 213. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 214. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 215. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 216. BRICS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 217. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 219. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 220. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 221. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 222. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 223. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 224. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 225. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 226. G7 METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 227. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 228. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 229. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 230. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 231. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 232. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 233. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 234. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 235. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 236. NATO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 238. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 239. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 240. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 241. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 242. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 243. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 244. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 245. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 246. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 250. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 251. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 252. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 253. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 254. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 255. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 256. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 258. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 260. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 261. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 262. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 263. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 264. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 265. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 266. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 270. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 271. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 272. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 273. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 274. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 276. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 277. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 288. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 289. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 290. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 291. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 292. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 293. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 294. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 295. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 296. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 297. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 298. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 299. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 300. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 301. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 302. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 303. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 304. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 305. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 306. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 307. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 313. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 314. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 315. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2017-2032 (USD MILLION)
TABLE 316. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 317. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 318. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 319. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY TREATMENT CLASSIFICATIONS, 2017-2032 (USD MILLION)
TABLE 320. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2017-2032 (USD MILLION)
TABLE 321. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES MELLITUS, 2017-2032 (USD MILLION)
TABLE 322. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THYROID DISORDERS, 2017-2032 (USD MILLION)
TABLE 323. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2017-2032 (USD MILLION)
TABLE 324. ITALY METABOLIC DISORDERS THE

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • Acadia Pharmaceuticals Inc.
  • Amgen Inc.
  • Amicus Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim International GmbH
  • CHIESI Farmaceutici S.p.A.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Luye Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Recordati Industria Chimica e Farmaceutica S.p.A
  • Sanofi S.A.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.

Table Information

Report AttributeDetails
No. of Pages195
PublishedSeptember 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 61.56 Billion
Forecasted Market Value ( USD ) by 2032 $ 89.68 Billion
Compound Annual Growth Rate6.3%
Regions CoveredGlobal
No. of Companies Mentioned32

Related Topics

Related Reports

Metabolic Disorder Therapeutics - Global Strategic Business Report - Product Image

Metabolic Disorder Therapeutics - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From
Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Metabolic Disorders Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 185 Pages
  • Global
From
Peptide Based Metabolic Disorder Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Peptide Based Metabolic Disorder Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Peptide Based Metabolic Disorders Therapeutics Market Report 2026 - Product Image

Peptide Based Metabolic Disorders Therapeutics Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Alpha Mannosidosis Market - Global Forecast 2026-2032 - Product Image

Alpha Mannosidosis Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From

About the Metabolic Disorder Drug Market

The Metabolic Disorder Drug market is a subset of the Endocrine and Metabolic Disorders Drugs market. It includes drugs used to treat metabolic disorders such as diabetes, obesity, and hyperlipidemia. These drugs are used to regulate the body's metabolism, which is the process of converting food into energy. Common drugs used to treat metabolic disorders include insulin, sulfonylureas, biguanides, thiazolidinediones, and GLP-1 agonists. These drugs are used to control blood sugar levels, reduce cholesterol, and promote weight loss. The Metabolic Disorder Drug market is highly competitive, with many companies offering a variety of drugs to treat metabolic disorders. Some of the major players in the market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. Other companies in the market include Boehringer Ingelheim, Takeda, and Pfizer. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.